Your browser is no longer supported. Please, upgrade your browser.
VYNE VYNE Therapeutics Inc. daily Stock Chart
VYNE Therapeutics Inc.
Index- P/E- EPS (ttm)-3.75 Insider Own2.10% Shs Outstand138.65M Perf Week-0.58%
Market Cap281.95M Forward P/E- EPS next Y-0.38 Insider Trans0.00% Shs Float138.08M Perf Month11.84%
Income-246.00M PEG- EPS next Q-0.16 Inst Own52.20% Short Float6.49% Perf Quarter-16.26%
Sales13.40M P/S21.04 EPS this Y-30.30% Inst Trans148.48% Short Ratio3.32 Perf Half Y-44.44%
Book/sh0.52 P/B3.27 EPS next Y49.30% ROA-209.80% Target Price- Perf Year-63.04%
Cash/sh0.58 P/C2.92 EPS next 5Y- ROE-400.60% 52W Range1.00 - 7.48 Perf YTD-63.36%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-78.61% Beta-
Dividend %- Quick Ratio4.70 Sales past 5Y- Gross Margin96.40% 52W Low60.00% ATR0.13
Employees180 Current Ratio4.90 Sales Q/Q- Oper. Margin- RSI (14)49.28 Volatility8.30% 8.76%
OptionableYes Debt/Eq0.46 EPS Q/Q-523.10% Profit Margin- Rel Volume1.45 Prev Close1.70
ShortableYes LT Debt/Eq0.46 Earnings- Payout- Avg Volume2.70M Price1.60
Recom1.90 SMA203.19% SMA50-0.84% SMA200-43.29% Volume482,065 Change-5.88%
Sep-23-20 08:00AM  
Sep-14-20 08:00AM  
Sep-11-20 08:35AM  
Sep-09-20 02:56PM  
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is headquartered in Bridgewater, New Jersey.